Guidance for the notification of serious breaches of GCP or the trial protocol

Table of Contents

Page Number(s):

A. Legal requirement

B. Purpose of the requirement

C Purpose of this guidance

D. Arrangements for notification

E. Identifying serious breaches

F. Potential actions by the MHRA

G. References

Appendix I: Notification Examples

Appendix II: Notification Form

Clinical Research News

Próximos ensaios clínicos

NCT04717258

Ainda não estou recrutando

Safe and Well Visits by the Fire and Rescue Service to Prevent Falls and Improve Quality of Life in Older People

Condições: Accidental Fall; Quality of Life; Aged
NCT04717284

Ainda não estou recrutando

A Self-compassion Intervention for Parents of Children With Inflammatory Bowel Disease (IBD)

Condições: Inflammatory Bowel Diseases
NCT04717297

Ainda não estou recrutando

Tailored Medication Management Intervention

Condições: Medication Non Adherence; Polypharmacy
NCT04717336

Recrutamento

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT

Condições: Cardiovascular Disease
NCT04717349

Recrutamento

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Condições: Disorders of Sex Development (DSD); Pediatric and Adolescent Cancers of the Genital Tract; Reproductive Endocrine Conditions in Puberty; Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
NCT04717362

Ainda não estou recrutando

The Effects of Natesto For Treatment Of Hypogonadism

Condições: Hypogonadism, Male; Infertility, Male; Testosterone Deficiency
NCT04717375

Ainda não estou recrutando

Study of BND-22 in Participants With Advanced Solid Tumors

Condições: Cancer
NCT04717388

Ainda não estou recrutando

Pathophysiology, Psycho-emotional and Cognitive Functioning Associated With Tinnitus

Condições: Tinnitus; Epilepsy, Temporal Lobe
NCT04717414

Ainda não estou recrutando

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Condições: Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Anemia
NCT04717466

Ainda não estou recrutando

Brain Changes in Psoriasis After Secukinumab Treatment

Condições: Psoriasis; Healthy

Guidance for the notification of serious breaches of GCP or the trial protocol

Clinical Research News

Próximos ensaios clínicos

Recent CRA jobs

Applications Administrator (CRM)

Analytical Specialist - Physical testing

Clinical Trial Coord - Client-dedicated

Associate Medical Director (Neurology)

GSK GICORS CTM

Assoc Mgr, Study Start Up

Safety Scientist II

(Sr) Project Manager - (FSP) Patient Access Programs

Logistics and Data Services Intern

Mgr Sites